
A study examined the impact of different antihyperglycemic medications on cardiovascular risks. Randomized clinical trials indicated that SGLT2 inhibitors and GLP-1 receptor agonists reduced adverse cardiovascular events compared to placebo. The effectiveness of older drugs (DPP-4 inhibitors, sulfonylureas) is less established. The study, using a pragmatic trial design and US VA healthcare databases, found that SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors were associated with lower risk of major adverse cardiovascular events (MACE) compared to sulfonylureas. SGLT2 inhibitors and GLP-1 receptor agonists demonstrated similar MACE risk. These findings provide real-world insight into second-line antihyperglycemic choices.
Like
Save
Share